Cybin D/B/A Helus Pharma (HELP)Healthcare | Biotechnology | Toronto, Canada | NasdaqGM
10.38 USD
-0.12
(-1.143%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 10.29 -0.09 (-0.088%) ⇩ (Oct. 14, 2026, 7:20 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 6:32 a.m. EDT
The investment case here is fractured by a brutal multi-year reality check. Despite the 'strong buy' analyst consensus and a lofty target price, the underlying business has suffered four consecutive years of negative annual returns, dragging the total value down nearly 88% over the last six years. This is not a temporary dip; it is a structural deterioration where the market has repeatedly punished the company's performance. Fundamentally, the picture is dire: negative earnings, negative free cash flow, and a return on equity that is deeply negative. The balance sheet, while currently liquid, is burning cash rapidly to fuel a pipeline that hasn't delivered consistent growth. The recent news of executive share sales adds a layer of skepticism regarding insider confidence. While the options market shows some speculative hope for a rebound, the heavy put positioning suggests traders are hedging against further pain rather than betting on immediate success. Until the company can demonstrate a sustained turnaround in revenue growth and profitability, the risk of permanent capital loss outweighs the potential for a speculative recovery. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.409453 |
| AutoTheta | 0.415401 |
| AutoETS | 0.415538 |
| MSTL | 0.420043 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 3.83 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 0.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 758,463,104 |
| Forward P/E | -5.81 |
| Beta | 0.54 |
| Previous Name | Cybin, Inc. |
| Website | https://www.helus.com |
As of Oct. 10, 2026, 6:32 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (e.g., $5.00 and $7.50 for November expiration), creating a dense 'insurance' wall against further downside. Conversely, call interest is concentrated at out-of-the-money strikes ($15.00 and $17.50), suggesting a speculative bet on a binary event or recovery rather than a steady grind higher. The implied volatility surface shows elevated premiums for deep out-of-the-money puts relative to calls, indicating the market prices in a higher probability of a crash than a moonshot rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.69354844 |
| Address1 | 100 King Street West |
| Address2 | Suite 5600 |
| All Time High | 128.44 |
| All Time Low | 2.964 |
| Ask | 11.87 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,546,960 |
| Average Daily Volume3 Month | 1,813,835 |
| Average Volume | 1,813,835 |
| Average Volume10Days | 1,546,960 |
| Beta | 0.539 |
| Bid | 6.79 |
| Bid Size | 2 |
| Book Value | 3.906 |
| City | Toronto |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.38 |
| Current Ratio | 10.969 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 10.47 |
| Day Low | 10.2 |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,710,600 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -166,936,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.546 |
| Enterprise Value | 591,999,616 |
| Eps Current Year | -3.71975 |
| Eps Forward | -1.7864074 |
| Eps Trailing Twelve Months | -4.15 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.0995 |
| Fifty Day Average Change | -1.7194996 |
| Fifty Day Average Change Percent | -0.14211328 |
| Fifty Two Week Change Percent | 69.35484 |
| Fifty Two Week High | 15.15 |
| Fifty Two Week High Change | -4.7699995 |
| Fifty Two Week High Change Percent | -0.31485146 |
| Fifty Two Week Low | 3.76 |
| Fifty Two Week Low Change | 6.62 |
| Fifty Two Week Low Change Percent | 1.7606382 |
| Fifty Two Week Range | 3.76 - 15.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,568,381,400,000 |
| Float Shares | 58,061,649 |
| Forward Eps | -1.7864074 |
| Forward P E | -5.810545 |
| Free Cashflow | -82,425,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 100 |
| Fullday Change | -0.22000027 |
| Fullday Change Percent | -2.0952406 |
| Fullday Price | 10.38 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12880999 |
| Held Percent Institutions | 0.41311002 |
| Implied Shares Outstanding | 73,069,668 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-01-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Last Split Date | 1,726,704,000 |
| Last Split Factor | 1:38 |
| Long Business Summary | Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada. |
| Long Name | Cybin D/B/A Helus Pharma |
| Market | us_market |
| Market Cap | 758,463,104 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_666815486 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -171,204,000 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 964,076,411 |
| Number Of Analyst Opinions | 10 |
| Open | 10.41 |
| Operating Cashflow | -140,792,992 |
| Operating Margins | 0.0 |
| Phone | 908 764 8385 |
| Post Market Change | -0.08829975 |
| Post Market Change Percent | -0.85067195 |
| Post Market Price | 10.2917 |
| Post Market Time | 1,792,020,002 |
| Prev Name | Cybin, Inc. |
| Previous Close | 10.5 |
| Price Eps Current Year | -2.7905102 |
| Price Hint | 2 |
| Price To Book | 2.6574502 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.757 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.09091 |
| Region | US |
| Regular Market Change | -0.119999886 |
| Regular Market Change Percent | -1.142856 |
| Regular Market Day High | 10.47 |
| Regular Market Day Low | 10.2 |
| Regular Market Day Range | 10.2 - 10.47 |
| Regular Market Open | 10.41 |
| Regular Market Previous Close | 10.5 |
| Regular Market Price | 10.38 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 1,053,855 |
| Return On Assets | -0.44382998 |
| Return On Equity | -0.86939 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 73,060,172 |
| Shares Percent Shares Out | 0.047399998 |
| Shares Short | 3,464,860 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,020,958 |
| Short Name | Helus Pharma Inc. |
| Short Ratio | 2.02 |
| Source Interval | 15 |
| State | ON |
| Symbol | HELP |
| Target High Price | 70.22638 |
| Target Low Price | 14.9191675 |
| Target Mean Price | 40.220898 |
| Target Median Price | 43.3818 |
| Total Cash | 166,364,992 |
| Total Cash Per Share | 2.277 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.537125 |
| Two Hundred Day Average Change | 2.842875 |
| Two Hundred Day Average Change Percent | 0.37718293 |
| Type Disp | Equity |
| Volume | 1,053,855 |
| Website | https://www.helus.com |
| Zip | M5X 1C9 |